November 5

HAMBURG, Germany, November 7, 2011 - - Newly founded EU-Latin America and Caribbean Foundation becomes operational The newly-founded EU-Latin America and Caribbean Foundation (EU-LAC) opened its headquarters today in the north German port city of Hamburg.

HOERSHOLM, Denmark & SAN DIEGO, November 5, 2011 - - New Phase 2a clinical data to be presented in late-breaking oral presentation at AASLD - - Miravirsen given as a four-week monotherapy treatment provided robust, dose-dependent antiviral activity with a mean reduction of 2 to 3 logs from baseline in Hepatitis C Virus (HCV) RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end of therapy - Four out of nine patients treated at the highest dose with miravirsen became HCV RNA undetectable during the study, providing clinicalevidence thatmiravirsen'sunique mechanism-of-action offers high barrier to viral resistance and the potential for treatment cures with monotherapy - Miravirsen, the first microRNA-targeted drug to enter clinical trials, works by inhibiting miR-122, a microRNA required for HCV accumulation, was well tolerated in patients with chronic HCV infection - Miravirsen's long-lasting suppression of HCV RNA, high barrier to viral resistance, low propensity for drug interactions and favorable tolerability profile holdspromise as pivotal new treatment option given as monotherapy or in combination with direct acting antiviral agents as an interferon-free treatment to eradicate chronic HCV infection in multiple genotypes Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, presents new data from the Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was maintained for more than four weeks beyond the end of therapy.

SAN FRANCISCO, November 5, 2011 - Data presented at AASLD 2011 highlights efficacy in typically hard to treat patients NOT INTENDED FOR US JOURNALISTS Janssen Pharmaceutica NV (Janssen), today presented new data for INCIVO (telaprevir) at the American Association for the Society of Liver Disease (AASLD) Annual Meeting, highlighting the safety and efficacy of a telaprevir based regimen in cirrhotic patients who had previously failed treatment.

THE HAGUE, Netherlands, November 5, 2010 - Representatives from seven international non-governmental organizations (NGOs) receiving funding from the Dutch Ministry of Foreign Affairs Strategic Alliances with International NGOs (SALIN) program gathered in The Hague today to share results with leading officials on their efforts to reduce maternal mortality and guarantee universal access to reproductive health services.

CALGARY, Alberta, November 5, 2010 - In the news release, "BNK Petroleum inc.